New data not so good for Boston Scientific’s Watchman anti-stroke device
Abiomed touts survival rates for its Impella right-side heart pump | TCT 2014 Roundup
Abiomed (NSDQ:ABMD) got some Wall Street love today after releasing positive outcomes from a clinical trial of its minimally invasive Impella Right Percutaneous heart pump.
Researchers reported an overall 73% 30-day survival rate in the small study of patients with right ventricular heart failure, according to data Abiomed released during the Transcatheter Cardiovascular Therapeutics conference in Washington D.C.
TCT 2014: Another trial shows no benefit for renal denervation in hypertension
TCT 2014: Medtronic’s IN.PACT Admiral beats PTA in outcomes, costs
TCT 2014: Boston Scientific’s 1-year data on Lotus TAVI device
TCT 2014 Roundup
Here’s a look at some of the news coming out of Washington at the 26th annual Transcatheter Cardiovascular Therapies conference this week:
TCT 2014: Is renal denervation dead or alive?
The efficacy of renal denervation is in doubt and should be confirmed or ruled out in treating resistant hypertension, according to an expert panel in a debate over the once high-flying technology at the Transcatheter Cardiovascular Therapeutics conference in Washington.
TCT 2014: TAVI takes center stage
St. Jude Medical hits ‘pause’ on Portico TAVI device
Stealthy mitral valve maker emerges at TCT 2014 | MassDevice.com On Call
MASSDEVICE ON CALL — Bad timing and a financial crisis nearly buried MVRx and its mitral valve repair technology forever, but the company’s founders finally revealed their progress over the weekend at the Transcatheter Cardiovascular Therapeutics conference.
MassDevice Network
@MassDevice
LinkedIn
YouTube